134 related articles for article (PubMed ID: 28546502)
41. Neutralization of IL-6 and TNF-α ameliorates intestinal permeability in DSS-induced colitis.
Xiao YT; Yan WH; Cao Y; Yan JK; Cai W
Cytokine; 2016 Jul; 83():189-192. PubMed ID: 27155817
[TBL] [Abstract][Full Text] [Related]
42. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist.
Butler DM; Maini RN; Feldmann M; Brennan FM
Eur Cytokine Netw; 1995; 6(4):225-30. PubMed ID: 8789287
[TBL] [Abstract][Full Text] [Related]
43. The IL-17 pathway as a major therapeutic target in autoimmune diseases.
Hu Y; Shen F; Crellin NK; Ouyang W
Ann N Y Acad Sci; 2011 Jan; 1217():60-76. PubMed ID: 21155836
[TBL] [Abstract][Full Text] [Related]
44. Cytokine and anti-cytokine strategies in inflammatory reaction modulation.
Delannoy I; Lekeux P; Miossec P
Vet Res; 1993; 24(6):449-67. PubMed ID: 8111428
[TBL] [Abstract][Full Text] [Related]
45. Signalling pathways of the TNF superfamily: a double-edged sword.
Aggarwal BB
Nat Rev Immunol; 2003 Sep; 3(9):745-56. PubMed ID: 12949498
[TBL] [Abstract][Full Text] [Related]
46. Anticytokine therapy, especially anti-interferon-gamma, as a pathogenetic treatment in TH-1 autoimmune diseases.
Skurkovich S; Skurkovich B
Ann N Y Acad Sci; 2005 Jun; 1051():684-700. PubMed ID: 16127009
[TBL] [Abstract][Full Text] [Related]
47. Anti-inflammatory activity of IL-37 in asthmatic children: Correlation with inflammatory cytokines TNF-α, IL-β, IL-6 and IL-17A.
Charrad R; Berraïes A; Hamdi B; Ammar J; Hamzaoui K; Hamzaoui A
Immunobiology; 2016 Feb; 221(2):182-7. PubMed ID: 26454413
[TBL] [Abstract][Full Text] [Related]
48. Gene of the month: Interleukin 6 (IL-6).
Ataie-Kachoie P; Pourgholami MH; Richardson DR; Morris DL
J Clin Pathol; 2014 Nov; 67(11):932-7. PubMed ID: 25031389
[TBL] [Abstract][Full Text] [Related]
49. Icariin inhibits TNF-α/IFN-γ induced inflammatory response via inhibition of the substance P and p38-MAPK signaling pathway in human keratinocytes.
Kong L; Liu J; Wang J; Luo Q; Zhang H; Liu B; Xu F; Pang Q; Liu Y; Dong J
Int Immunopharmacol; 2015 Dec; 29(2):401-407. PubMed ID: 26507164
[TBL] [Abstract][Full Text] [Related]
50. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.
Walters HM; Pan N; Lehman TJ; Adams A; Kalliolias GD; Zhu YS; Santiago F; Nguyen J; Sitaras L; Cunningham-Rundles S; Walsh TJ; Toussi SS
Clin Exp Immunol; 2016 Jun; 184(3):308-17. PubMed ID: 26934060
[TBL] [Abstract][Full Text] [Related]
51. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation.
Booth AD; Jayne DR; Kharbanda RK; McEniery CM; Mackenzie IS; Brown J; Wilkinson IB
Circulation; 2004 Apr; 109(14):1718-23. PubMed ID: 15037536
[TBL] [Abstract][Full Text] [Related]
52. Cytokines and anti-cytokines as therapeutics--an update.
Tayal V; Kalra BS
Eur J Pharmacol; 2008 Jan; 579(1-3):1-12. PubMed ID: 18021769
[TBL] [Abstract][Full Text] [Related]
53. Saucerneol F inhibits tumor necrosis factor-α and IL-6 production by suppressing Fyn-mediated pathways in FcεRI-mediated mast cells.
Lu Y; Piao D; Zhang H; Li X; Chao GH; Park SJ; Chang YC; Kim CH; Murakami M; Jung SH; Choi JH; Son JK; Chang HW
Food Chem Toxicol; 2013 Sep; 59():696-702. PubMed ID: 23851146
[TBL] [Abstract][Full Text] [Related]
54. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.
Charles P; Elliott MJ; Davis D; Potter A; Kalden JR; Antoni C; Breedveld FC; Smolen JS; Eberl G; deWoody K; Feldmann M; Maini RN
J Immunol; 1999 Aug; 163(3):1521-8. PubMed ID: 10415055
[TBL] [Abstract][Full Text] [Related]
55. Should we consider tumor necrosis factor as the only target in spondyloarthritides?
Ferraccioli G; Gremese E
J Rheumatol Suppl; 2012 Jul; 89():94-6. PubMed ID: 22751604
[TBL] [Abstract][Full Text] [Related]
56. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation.
Joosten LA; Helsen MM; Saxne T; van De Loo FA; Heinegard D; van Den Berg WB
J Immunol; 1999 Nov; 163(9):5049-55. PubMed ID: 10528210
[TBL] [Abstract][Full Text] [Related]
57. [TNF inhibitors: a new therapeutic perspective in chronic inflammatory diseases in rheumatology?].
Fenner H
Z Rheumatol; 1995; 54(3):158-64. PubMed ID: 7660686
[TBL] [Abstract][Full Text] [Related]
58. Inflammatory Kinetics and Efficacy of Anti-inflammatory Treatments on Human Nucleus Pulposus Cells.
Walter BA; Purmessur D; Likhitpanichkul M; Weinberg A; Cho SK; Qureshi SA; Hecht AC; Iatridis JC
Spine (Phila Pa 1976); 2015 Jul; 40(13):955-63. PubMed ID: 25893355
[TBL] [Abstract][Full Text] [Related]
59. TNF receptor-associated factor-2 is involved in both IL-1 beta and TNF-alpha signaling cascades leading to NF-kappa B activation and IL-8 expression in human intestinal epithelial cells.
Jobin C; Holt L; Bradham CA; Streetz K; Brenner DA; Sartor RB
J Immunol; 1999 Apr; 162(8):4447-54. PubMed ID: 10201981
[TBL] [Abstract][Full Text] [Related]
60. Molecular mechanisms of inflammatory bone damage: emerging targets for therapy.
Herman S; Krönke G; Schett G
Trends Mol Med; 2008 Jun; 14(6):245-53. PubMed ID: 18468489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
